In people with obesity or type 2 diabetes, the way their bodies respond to insulin and niacin in suppressing free fatty acids varies from person to person, but those who do not respond well to one of these agents typically also do not respond well to the other.

40

Pro

0

Against

Evidence from Studies

Supporting (1)

40

Community contributions welcome

40

Adipose Tissue Resistance to the Antilipolytic Effect of Insulin and Niacin in Humans With Obesity.

Randomized Controlled Trial

Human

2026 Apr 1

In people with obesity or diabetes, if their body doesn’t respond well to insulin stopping fat release, it also usually doesn’t respond well to niacin doing the same thing—even though the two work differently. This suggests a common problem deeper in the fat cells.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Adipose Tissue Resistance to the Antilipolytic Effect of Insulin and Niacin in Humans With Obesity.

Score: 40

DOI: 10.2337/db25-0979

Similar Assertions

In people with obesity or type 2 diabetes, the less effectively insulin reduces fat release from fat cells, the less effectively niacin does too, suggesting both substances are affected by the same underlying problem in how fat breakdown is controlled.

40

0

86%

In people with obesity or type 2 diabetes, insulin and niacin reduce the release of free fatty acids through different early molecular mechanisms, but both ultimately affect the same later regulatory proteins to achieve similar results.

40

0

78%

In people with obesity or type 2 diabetes, niacin still reduces fat breakdown in adipose tissue even when the usual insulin signaling pathways are less active, indicating it may use alternative biological mechanisms to achieve this effect.

40

0

74%